告别“裸泳”，港股开启创新药IPO盛宴

Core Insights - The Hong Kong stock market is experiencing a new wave of IPOs for innovative drug companies, marking a shift from the previous hype-driven valuations to a more rational, results-oriented approach [1][4] - The current IPO participants are more diverse, including biotech firms and those pursuing dual listings or spin-offs [1][4] Group 1: IPO Activity - As of January, seven innovative drug companies have submitted IPO applications to the Hong Kong Stock Exchange, including companies like Boryung Biopharma and Xiansheng Zaiming [5] - Two companies, Precision Medical and Rebio Biotech, have successfully listed, raising over 4 billion yuan in total [6] - The choice of Hong Kong for listing is influenced by the fact that many companies are still in the loss-making stage, aligning with the HKEX's 18A/18C rules for unprofitable tech firms [6] Group 2: Financial Performance and Valuation - DiZhe Pharmaceutical, which is already listed on the STAR Market, aims for a dual listing and has a market cap exceeding 25 billion yuan, with a revenue of 586 million yuan in the first three quarters of 2025, reflecting a growth of over 70% [6] - Despite significant revenue growth, DiZhe reported a net loss of 580 million yuan, indicating ongoing challenges in profitability and cash flow [6] - Other companies like Zailing Biotech and Yinuo Micro have also attracted significant investments, with post-financing valuations of 3.41 billion yuan and 485 million USD, respectively [7] Group 3: Market Evolution - The previous IPO wave from 2018 to 2021 was characterized by speculative investments, leading to a high failure rate among newly listed companies, with a 15% and nearly 80% failure rate in 2020 and 2021, respectively [8][9] - The current IPO landscape shows a shift towards companies with more advanced clinical data and a focus on technology platforms, moving away from mere story-driven valuations [11] - The new IPOs are primarily backed by teams with international experience and robust ownership structures, enhancing their appeal to investors [12] Group 4: Unique Listing Strategies - This round of IPOs includes unique strategies such as dual listings and spin-offs, exemplified by DiZhe Pharmaceutical and Xiansheng Zaiming [13][14] - DiZhe has seen significant insider selling during its fundraising period, indicating a mix of personal financial needs and tax considerations [13] - Xiansheng Zaiming is in a high-investment phase, with over 1.5 billion yuan allocated for R&D in 2023 and 2024, reflecting a post-financing valuation exceeding 8.5 billion yuan [14]